Diferencias microbiológicas en pacientes con exacerbación severa de EPOC con o sin consolidación neumónica


Autoria(s): Torres Caro, Maria Cristina
Contribuinte(s)

Aguirre, Carlos

Beltran, Johny

Data(s)

03/12/2012

Resumo

La EPOC es una causa importante de morbilidad y mortalidad en el mundo y su prevalencia en Bogotá alcanza hasta 8,5%. Las exacerbaciones están asociadas a deterioro funcional y de la calidad de vida por lo que se consideran un factor cardinal de la enfermedad. En la literatura se ha descrito que las infecciones por bacterias y/o virus son las responsables del 78% de las exacerbaciones. Estos datos han sido descritos en poblaciones diferentes y no hay datos en la literatura que muestren cual es la epidemiología local de las exacerbaciones de EPOC y menos aún de aquellas que se asocian a consolidaciones neumónicas. Objetivo: Comparar la microbiología de las exacerbaciones severas de la EPOC que requieren ingreso a UCI con y sin infiltrados alveolares. Materiales y métodos: Estudio de corte transversal en el que se estudiaron pacientes con EPOC que ingresaron a la UCI Médica de la FCI-IC por exacerbación severa, asociada o no a infiltrados alveolares. Se tomaron muestras de microbiología, serológicas y radiografía de tórax para evaluar la etiología de la exacerbación, si se asocia a coinfección viral y a consolidación neumónica o no. Resultados: No se encontró una diferencia estadísticamente significativa en la microbiología de los diferentes grupos evaluados. Se encontró un resistencia global del 24% y llama la atención que hay una alta prevalencia de Serratia Marcescens AMPc entre los 2 grupos, germen que no está descrito como patógeno común en la literatura. Se encontraron diferencias en cuanto a factores de riesgo para presentar neumonía asociada como lo son un mayor índice de paquetes/año (55.1.6 vs. 36.3 paq/año, sig.=0.021). Así mismo se demostró que los pacientes con neumonía asociada presentan mayor necesidad de IOT (48.9 vs. 23.9, sig.=0.013). No hay diferencia significativa en desenlaces como mortalidad (20.5 vs. 13.0, sig.=0.346). Conclusiones: A pesar de no haber diferencia microbiológica entre los 2 grupos se encontraron variables como factores de riesgo y variables clínicas que pueden ayudar a proponer planes de manejo en los dos escenarios. El hecho de encontrar un paciente con neumonía asociada al cuadro de exacerbación no debe afectar en la toma de decisiones en relación al tratamiento antibiótico.

COPD is an important cause of morbidity and mortality around the world and it's prevalence in Bogotá rises up to 8,5%. Acute exacerbations affect functionality and life quality and therefore are considerated a cardinal factor in the disease. It has been described in the literature that bacteria and virus account for 78% of the exacerbations. However it is important to remark that these observations have been described in different populations, and there are no available data that show the local epidemiology of COPD exacerbations and also not from the ones associated with a pneumonic consolidation. Objective: To describe the microbiology from COPD severe exacerbations which require admission to the ICU with and without pneumonic consolidation. Materials and methods: We did a cross sectional study in which the population were patients diagnosed with COPD admitted to the ICU from FCI-IC because of a severe exacerbation associated or not with a pneumonic consolidation. We took microbiologic and serologic sample to study the etiology of the exacerbation and a thorax radiography to see if it was associated or not with pneumonia. Results: We did not found a difference that was statistically significative between the two evaluated groups. However we found a global bacterial resistance of 24% and an important prevalence of Serratia marcescens AMPc between the groups, which is not described as a common pathogen in the literature. We found differences in risk factors in the patients who had pneumonia such as a higher tobacco index (55.1.6 vs. 36.3 pack/ year, sig.=0.021). We also found that patients with associated pneumonia needed more ventilatory support with ventilation (48.9 vs. 23.9, sig.=0.013), and that there were no difference in mortality between the 2 groups (20.5 vs. 13.0, sig.=0.346). Conclusions: Even tough we did not found a significant difference in the microbiology from the two studied groups there are variables as risk factors and clinical variants of presentation that could help propose a therapy plan in the different scenarios of the disease. There should not be changes in the antibiotic therapy depending on associated pneumonia.

Formato

application/pdf

Identificador

http://repository.urosario.edu.co/handle/10336/4180

Idioma(s)

spa

Publicador

Facultad de Medicina

Direitos

info:eu-repo/semantics/closedAccess

Fonte

reponame:Repositorio Institucional EdocUR

instname:Universidad del Rosario

J. Vestbo, A. Agusti, A. Anzueto, P. Barnes, P. Calverley, M. Decramer, L. Fabbri, Y. Fukuchi, P. Jones, F. Martínez, K. Rabe, R. Rodríguez-Roisin, D. Sin, J. Wedzicha, The Global initiative for chronic obstructive lung disease. Update 2009 Disponible en la web: http://www.goldcopd.org/.

Caballero A, Torres C, et al. Prevalence of COPD in Five Colombian Cities Situated at Low, Medium, and High Altitude. (PREPOCOL Study) Chest 2008; 133; 343-349.

Wedzicha J, Seemungal T, et al. COPD exacerbations: defining their cause and prevention. Lancet 2007; 370: 786–96.

Mannino D, Buist S. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: 765–73.

Republica de Colombia, Censo general 2005, Disponible en la web: http://www.dane.gov.co/censo/files/libroCenso2005nacional.pdf.

Bazurto M, Parada O, Martinez CE. Mortalidad en exacerbaciones agudas de la EPOC. Revista Colombiana de Neumología, Vol. 14; (3), Sept. 2002

Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204

Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995; 108:43S–52S

Celli B, Barnes P, Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007; 29: 1224–1238

Seemungal T, Donaldson G, et al. Time Course and Recovery of Exacerbations in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2000, (161): 1608–1613.

Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002; 121:121S–126S.

Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA, Maldonado JA, Gallego M and the Study Group of Bacterial Infection in COPD. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 1999;116:40–46

Papi A, Bellettato C, et al. Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations. Am J Respir Crit Care Med Vol 173;1114–1121, 2006

Eller J, Ede A, et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998;113:1542–1548.

Cameron RJ, de Wit D, Welsh TN, et al. Virus infection in exacerbations of chronic obstructive pulmonary disease requiring ventilation. Intensive Care Med 2006; 32:1022–1029.

Miravitlles M. Epidemiology of Chronic Obstructive Pulmonary Disease Exacerbations. Clin Pulm Med 2002;9(4):191–197.

Bandi V, Apicella MA, et al. Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med 2001; 164:2114–2119

Van Schifgaarde M, Eijk PP, et al. Haemophilus influenzae localized in epithelial cell layers is shielded from antibiotics and antibody mediated bactericidal activity. Microbial Pathogen 1999; 26:249–262

Monso E, Josep Morera. Bacterial Colonization in Chronic Obstructive Pulmonary Disease: Is It Related to Evolution? Clin Pulm Med 2001;8(6):313–317.

Soler N, Torres A, et al. Bronchial Microbial Patterns in Severe Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) Requiring Mechanical Ventilation. Am J Respir Crit Care Med Vol 157. 1498–1505, 1998

Sethi S, Murphy TF. Bacterial Infection in Chronic Obstructive Pulmonary Disease in 2000: a State-of-the-Art Review Clin Microbiol Rev 2001, 14(2):336.

Cabello H, Torres A, et al. Distal airway bacterial colonisation in healthy subjects and chronic lung diseases: a bronchoscopic study. Eur Respir J 10:1137–1144, 1997

Gorse G, O’Connor TZ, Young SL, et al. Impact of winter respiratory virus season on patients with COPD and association with influenza vaccination. Chest 2006; 130:1109–1116

Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med. 1995;152:1316–1320

Craig JE, Cliffe A, et al. Survival of nontypeable Haemophilus influenzae in macrophages. FEMS Microbiol Lett 2001; 203:55–61.

Angel JB, Wright L, et al. Granulocyte inflammatory markers and airway infection during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:349–355

Papi A, Message SD, Papadopoulos NG, et al. Respiratory viruses and asthma. In: Chung KF, Fabbri LM, editors. European respiratory monograph: asthma. Sheffield, UK: European Respiratory Society; 2003. pp. 223–228.

Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, et al. Respiratory Viruses, Symptoms, and Inflammatory Markers in Acute Exacerbations and Stable Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med Vol 164. pp 1618–1623, 2001.

Arruda E, Boyle TR, Winther B, et al. Localization of human rhinovirus replication in the upper respiratory tract by in situ hybridization. J Infect Dis 1995; 171:1329–1333.

Sykes A, Mallia P, Johnston SL. Diagnosis of Pathogens in Exacerbations of Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc Vol 4. pp 642–646, 2007

Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations, Chest 2000; (117): 398s-401s.

Greenberg SB, Allen M, Wilson J, Atmar RL. Respiratory viral infection in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:167– 173

Huerta A, Domíngo R, Soler N, EPOC y neumonía, Arch Bronconeumol. 2010;46(Supl 3):28-31

Ko FW, Ip M, Chan PK, Ng SS, Chau SS, Hui DS. A one-year prospective study of infectious etiology in patients hospitalized with acute exacerbations of COPD and concomitant pneumonia. Respir Med. 2008;102:1109-16.

Sethi S, Murphy T. Infection in the Pathogenesis and Course of Chronic Obstructive Pulmonary Disease, N Engl J Med 2008;359:2355-65.

Yi ZM, Yang H, Xiang XD. Characteristics of bacteriology and drug sensitivity in patients with COPD combined with pneumonia, Hunan Yi Ke Da Xue Xue Bao. 2003 Jun;28(3):272-4.

Torres A, Ewig S. The strange case of community – Acquired pneumonia in COPD. Chest 2011;139;483-485

File TM , Monte SV, Schentag JJ, Paladino JA, Klugman KP, Lavin B, et al. A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics /pharmacodynamics of the antibiotic. Int J Antimicrob Agents. 2009;33:58- 64.

Daubin C, Parienti JJ, Fradin S, Vabret A, Ramakers M, Terzi N, et al. Procalcitonin levels and bacterial aetiology among COPD patients admitted to the ICU with severe pneumonia: a prospective cohort study. BMC Infect Dis. 2009;9:157

Fusté E, galisteo GJ, Jover L, Vinuesa T, Villa TG, Vilas M. Comparison of antibiotic susceptibility of old and current Serratia. Future Microbiol (2012) 7(6), 781-786

Rice SA, Koh KS, Queck SY, Labbate M, Lam KW, Kjelleberg S. Biofilm formation and sloughing in Serratia marcescens are controlled by quorum sensing and nutrient cues. J Bacteriol 2005, 187(10):3477-3485

Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhales corticosteroids in patients with stable chronic obstructive pulmonary disease, A systematic Review and Meta – analysis. Jama 2008; 300(20):2407-2416

Randhawa AP, Hawn TR. Toll – like receptors: their roles in bacterial recognition and respiratory infections. Expert Rev Anti Infect Ther 2008; 6(4), 479-495

TEME 0126 2012

Palavras-Chave #ENFERMEDAD PULMONAR OBSTRUCTIVA CRÓNICA (EPOC) #ENFERMEDADES OBSTRUCTIVAS DE LOS PULMONES #ENFERMEDADES RESPIRATORIAS #NEUMONÍA #COPD #Pneumonia #Microbiology #Epidemiology
Tipo

info:eu-repo/semantics/bachelorThesis

info:eu-repo/semantics/acceptedVersion